The Food and Drugs Administration (FDA) announced that the label requirements has been updated for the Mifepristone – also called Mifeprex –being approved as a supplemental application based on the data and information submitted by the drug manufacturer, making easier to prescribe this drug in states that have laws regulating its use.
This label change brings the drug into alignment with common medical practices in 47 states and will make this drug more accessible to women whose states’ lawmakers –Ohio, Texas and North Dakota – had required doctors to prescribe the drug first, which means that into these states the FDA’s new label will make this abortion-inducer drug easier to get.
How this pill does works?
It’s basically for a two-step process induced abortion when first the mifepristone is taken, and two days later, the misoprostol is taken. Maybe the most significant update to the FDA is the recommendations to don’t use to describe the pill to those who can oversee its use as an abortion pill.
This “abortion drug” was legally available and approved in 2000, where back then doctors determinate that it was effective at lower doses, and might be used on pregnant women up to 70 days women’ last period instead of 49 days as it was used to. At that time, it was considered a cutoff in the abortion-related theme, but after a 16-year hiatus, it hasn’t changed a thing.
University of California’s obstetric professor Daniel Grossman stated that this change it’s the best example of evidence-practice on safety and effectiveness on this treatments might be, also adding that several doctors were using this method off-label since 2001.
A Debate for the New-Born
The National Right to Live committee stated that this new protocol is just serving the interest of the abortion industry by reducing the sources and time required to administrate a drug to a pregnant woman.
Also, this updated label is related to evidence-based medicine, having the potential to expand the abortion access to women, but hey, who says this law can’t change again? It may vary on what’s the impact of refreshing this label and getting more “flexible” with the requirements that the “White bombshell” pill might cause these days.
Source: The New Yorker